This is a snippet of the transcript, sign up to read more.
First, is the relationship or lack thereof and second, is the breadth of their product portfolio. Zoetis has a wide portfolio offering producers convenience, consistency and volume discounts across categories. Large producers drive the business because of theirs and their veterinarian's relationship with a company.
This is a snippet of the transcript, sign up to read more.
The American Angus Association partnered with Neogen, a major competitor of Zoetis, to create a new genetic test. It was owned by the association and was superior to the test Zoetis had in place, and cost half the price. When it was introduced, Zoetis had 80% market share with our members, and most thought, in a year, they would be lucky to have 20%, but it only fell 50% because of those strategic account relationship agreements they had in place. Even though they knew the other product was better, they realized Zoetis had been charging them twice as much because Zoetis dropped the price to match the new product. It didn't matter because they knew if they walked away and reduced their volume, it would also affect the price on all the other products.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.